Operating under the Medical Devices umbrella, Pacific Biosciences of California, Inc. is a healthcare company. Pacific Biosciences of California, Inc. At a $447.3M market cap, Pacific Biosciences of California, Inc. ranks as a small-cap company within healthcare. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Market Cap
$447.3M
Beta
2.29
P/E (TTM)
—
P/E (Fwd)
-3.63
EPS (TTM)
$-0.41
EPS (Fwd)
$-0.40
ROE
-273.6%
ROA
-12.0%
Cash
$276.0M
Total Debt
$706.4M
Free CF
-$48.2M
52W Change
5.1%
Annual Financials
Cash vs Debt
The company holds $276.0M in cash, though total debt stands at $706.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$48.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -273.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $128.3M (2022) to $160.0M (2025), reflecting a 25% increase over the period.
A beta of 2.29 means PACB is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PACB.